Schroder Investment Management Group bought a new position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 29,776 shares of the biopharmaceutical company’s stock, valued at approximately $3,645,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Guardian Life Insurance Co. of America boosted its holdings in Alexion Pharmaceuticals by 0.7% during the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 6 shares during the last quarter. Eqis Capital Management Inc. boosted its holdings in Alexion Pharmaceuticals by 0.6% during the second quarter. Eqis Capital Management Inc. now owns 6,776 shares of the biopharmaceutical company’s stock worth $824,000 after buying an additional 38 shares during the last quarter. Cleararc Capital Inc. boosted its holdings in Alexion Pharmaceuticals by 1.0% during the first quarter. Cleararc Capital Inc. now owns 5,495 shares of the biopharmaceutical company’s stock worth $666,000 after buying an additional 53 shares during the last quarter. Seven Bridges Advisors LLC boosted its holdings in Alexion Pharmaceuticals by 2.1% during the second quarter. Seven Bridges Advisors LLC now owns 2,638 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 53 shares during the last quarter. Finally, Geneva Advisors LLC boosted its holdings in Alexion Pharmaceuticals by 0.7% during the second quarter. Geneva Advisors LLC now owns 11,408 shares of the biopharmaceutical company’s stock worth $1,388,000 after buying an additional 82 shares during the last quarter. Hedge funds and other institutional investors own 94.17% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally published by Daily Political and is the property of of Daily Political. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/09/21/schroder-investment-management-group-takes-3-65-million-position-in-alexion-pharmaceuticals-inc-alxn.html.

A number of equities analysts have issued reports on ALXN shares. Barclays PLC restated an “overweight” rating and set a $155.00 target price on shares of Alexion Pharmaceuticals in a report on Wednesday, May 24th. Stifel Nicolaus restated a “buy” rating and set a $157.00 target price on shares of Alexion Pharmaceuticals in a report on Wednesday, May 24th. BMO Capital Markets reaffirmed an “outperform” rating and set a $158.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $158.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. Finally, Deutsche Bank AG dropped their price target on Alexion Pharmaceuticals from $160.00 to $153.00 and set a “buy” rating on the stock in a research report on Thursday, May 25th. Five investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and three have assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $157.21.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 142.92 on Thursday. Alexion Pharmaceuticals, Inc. has a 52-week low of $96.18 and a 52-week high of $149.34. The firm’s 50 day moving average price is $139.14 and its 200 day moving average price is $124.77. The firm has a market cap of $31.90 billion, a price-to-earnings ratio of 61.98 and a beta of 1.40.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, topping the consensus estimate of $1.08 by $0.48. The firm had revenue of $912.00 million during the quarter, compared to the consensus estimate of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The company’s quarterly revenue was up 21.1% compared to the same quarter last year. During the same period in the prior year, the business posted $1.13 earnings per share. Equities research analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current fiscal year.

In other news, Director Ann M. Veneman sold 700 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $137.74, for a total value of $96,418.00. Following the completion of the sale, the director now directly owns 6,315 shares of the company’s stock, valued at $869,828.10. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Julie O’neill sold 11,160 shares of the stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $140.00, for a total value of $1,562,400.00. Following the completion of the sale, the executive vice president now directly owns 26,704 shares of the company’s stock, valued at $3,738,560. The disclosure for this sale can be found here. Over the last three months, insiders sold 17,070 shares of company stock valued at $2,416,869. Company insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.